The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer-Reference-Cited by-同舟云学术

The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer

Published:2017-06-18 Issue:11 Volume:44 Page:1806-1812
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Öbek Can, ,Doğanca Tünkut,Demirci Emre,Ocak Meltem,Kural Ali Rıza,Yıldırım Asıf,Yücetaş Uğur,Demirdağ Çetin,Erdoğan Sarper M.,Kabasakal Levent

Funder

Scientific Research Projects Coordination Unit of Istanbul University

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/article/10.1007/s00259-017-3752-y/fulltext.html

Reference31 articles.

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–79.

2. Heesakkers RA, Hovels AM, Jager GJ, van den Bosch HC, Witjes JA, Raat HP, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol. 2008;9(9):850–6.

3. Bouchelouche K, Choyke PL, Capala J. Prostate specific membrane antigen – a target for imaging and therapy with radionuclides. Discov Med. 2010;9(44):55–61.

4. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95.

5. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific Membrane Antigen;PET Clinics;2024-07

2. Prostate Cancer Metastasis to the Occipital Bone Detected on Prostate-specific Membrane Antigen Imaging: A Case Report;The Anatolian Journal of General Medical Research;2024-04-22

3. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-02

4. Correlación entre los índices estandarizados SUVmáx de la PET/TC con [68Ga]Ga-PSMA-I&T pre-prostatectomía radical y los resultados histopatológicos finales: un análisis en profundidad;Revista Española de Medicina Nuclear e Imagen Molecular;2024-03

5. Correlation between pre-radical prostatectomy standardized SUVmax ratios detected on 68Ga-PSMA-I&T PET/CT and final histopathology outcomes: an in-depth analysis;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2024-03